As part of PhRMA’s continuing work to address health inequalities, we are awarding $100,000 total in grants to fund four projects that will help improve health outcomes by addressing inequity in health care. Nearly 50 candidates nationwide submitted proposals for the PhRMA COVID-19 Collaborative Actions to Reach Equity (CAREs) grant program, announced in April as part of our observation of National Minority Health Month.
While PhRMA’s member companies are working tirelessly to find medicines and vaccines to combat COVID-19, we also recognize the need for evidence-based research and cross-sector partnership to tackle other key questions to address health inequity in communities of color that have been highlighted and exacerbated by the COVID-19 public health emergency. We are committed to working to fix the health care system so it works better for all Americans, and this is one piece in a series of solutions we’ve put forward to improve patient access and affordability.
The following projects will receive $25,000 each:
AltaMed Blood Pressure Program is a partnership with AltaMed Institute for Health Equity, American Heart Association and California State University to address underlying hypertension, a health disparity impacted by COVID-19, among minority populations in southeast Los Angeles. The partnership aims to facilitate at-home blood pressure monitoring; offer educational materials around hypertension risk factors, consequences and management; and provide support for medication adherence for hypertensive individuals who are at high risk of contracting and/or experiencing complications from COVID-19.
“At AltaMed Health Services Corporation, we have accelerated processes that allow us to ascend beyond traditional community health center services.” – Corina Martinez, Project lead of AltaMed Blood Pressure Program
National Spanish Language COVID-19 Prevention Messaging aims to address health information gaps in underlying health conditions and their impact on COVID-19 among Hispanic populations by providing essential up-to-date, first-hand COVID-19 information in Spanish. In partnership with Hispanic Communications Network, a communication campaign will activate radio, digital and social media to offer wide reaching communication to raise awareness of COVID-19 and the underlying risks to address unequal access to health information and disparities in Spanish-speaking communities.
“Despite Hispanics being the largest minority group in the United States, lack of access to health care and information remain salient issues that further reinforce a vicious cycle that hinders progress in the treatment of chronic conditions among Hispanic communities.” – Sindy Benavides, Chief Executive Officer of the LULAC Institute.
Comprehensive Medication Management Program for Vulnerable Populations aims to reduce risk for its patients – who are at high-risk, low-income and disproportionately African American – through chronic disease management and medication adherence improvement. Heart of Ohio Family Health Centers will work with the American Heart Association to target underserved patients with uncontrolled diabetes, hypertension and hyperlipidemia to provide nurse-led education, care coordination, and medication management while addressing barriers in access to care and free, healthy food.
“All the patients we serve at high-risk and vulnerable. Our facilities provide services regardless of a patient’s ability to pay.” - David Brewer, MBA, MS, RD, LD, CSOWM, CPHQ, LBBH, Project lead of Comprehensive Medication Management Program for Vulnerable Populations
Implicit Bias Training for Professionals and Community Leaders aims to address implicit bias, a key contributor to racial health disparities, to support health providers and community organizations in more equitable service delivery and reduction of health disparities by race. In partnership with other private and public local organizations in Louisiana, like the Center for Health Equity and Xavier University, the project will design, implement and evaluate training for health care providers to reduce implicit bias and offer a blueprint to inform policy and practice change to prevent future differential outcomes in COVID-19 and other conditions.
“The reliance on implicit bias is exacerbated by extreme stress in a number of settings. With health care systems currently overtaxed due to COVID-19, it is vitally important to invest in program designs that reduce the impact of implicit bias in order to prevent future differential outcomes in COVID-19 and other conditions by race.” - Ashley Politz, LMSW, Project lead of Implicit Bias Training for Professionals and Community Leaders
To learn more about the grant program, visit https://phrma.org/policy-paper/PhRMA-Health-Equity-Roundtable-Announces-CAREs-Grants.
Lori M. Reilly, Esq.
Lori M. Reilly is chief operating officer at PhRMA, providing executive level management, leadership and strategic direction for the organization. In this role, Reilly oversees PhRMA’s advocacy activities, including its federal, state and international government affairs and alliance development work. Reilly provides strategic leadership and works across PhRMA to develop and advocate for practical policy solutions that will lower costs for patients.
Reilly, named by the Washingtonian as one of the 250 most influential people in D.C., has a long record of working with members of Congress on a bipartisan basis and collaborating with stakeholders across the health care industry. Reilly is a frequent presenter on industry-related issues, including testifying before Congress on multiple occasions.
Reilly has over two decades of experience at PhRMA; prior to her current role, Reilly was the executive vice president of policy, research and membership at PhRMA, leading the development and implementation of legislative, regulatory and political strategies to advance policies that encourage patient access and medical innovation. She has also served as counsel at the U.S. House of Representatives Committee on Commerce and was Counsel to a member of the House Ways and Means Committee.
Reilly received a B.A. in political science from the University of Nebraska-Lincoln where she graduated with honors, and a J.D. from the University of Nebraska College of Law. She currently resides in Alexandria, Virginia with her husband and their four children.
Lori Reilly
https://www.linkedin.com/in/lorireillyphrma/
Chief Operating Officer
Recent events highlight progress on health equity
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
Hispanic Heritage Month: Fighting for Hispanic patients
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
How government price setting fails to address systemic health care inequities
Women’s Health Month: A conversation with Sage
Championing cancer equity: Our drive for healthier AANHPI communities
New analysis: Accelerated approval pathway is changing lives in underserved communities
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
WHO Pandemic Agreement offers opportunities and risks for American innovators
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
What you should know about protecting your health this fall
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
Key considerations as Congress works towards PAHPA reauthorization
Between hope and despair: Improving cancer outcomes
A conversation with Dr. Mike Ybarra on the current state of COVID-19
PhRMA awards grant to Emerson Diversity Health Foundation
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
Celebrating the success of the COVID-19 vaccines, and looking to the future
PhRMA submits comments to OSTP on enhancing clinical trial diversity
What we’ve learned from three years of fighting COVID-19
U.S. must address IP and market access barriers abroad to protect American innovation
Using traditional HTAs to determine coverage threatens patient access to medicine
Traditional HTAs keep diverse patients out of the conversation
Word of the Month: What is TRIPS?
TRIPS waiver expansion risks public health
Expanding the WTO intellectual property waiver will hurt American jobs
Traditional HTA methods treat everyone like the “average” patient
Word of the Month: Long COVID
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
Partnerships are driving global COVID-19 treatment access
The dangers of expanding the TRIPS waiver
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
Potential gene therapies bring hope to patients with sickle cell disease
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
A conversation with Barry Greene, CEO of Sage Therapeutics
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
Stephanie Dyson of BMS on reducing health disparities
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
What you need to know about newly authorized COVID-19 antiviral treatments
Guest post: Joining forces to combat the COVID-19 mental health crisis
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
Protecting U.S. innovation abroad to support economic and pandemic recovery
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
Navigating the patient experience in the time of COVID-19
Global COVID-19 vaccination matters now and for the future
Announcing CAREs Grant Round 4
Announcing CAREs Grant Round 4
Understanding breakthrough COVID-19 infections
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
The important role of antivirals in the fight against COVID-19
Understanding Long COVID-19
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
The impact of monoclonal antibodies and COVID-19 recovery
Recognizing National Immunization Awareness Month
Driving further innovation is critical to global vaccine equity
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
Increasing global access to vaccines by optimizing production
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
Guest Post: A patient’s story of the long-term health impacts of COVID-19
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
PhRMA awards $75,000 to fund initiatives to reduce health inequities
Watch: Building trust and enhancing clinical trial diversity
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
Americans 12 years of age and older are eligible for COVID-19 vaccines
PhRMA hosts first stakeholder workshop on clinical trial diversity
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
A year later: Reflections on the meaning of equity
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
Supporting India during the devastating coronavirus surge
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
The Biden Administration allows politics to upend a pragmatic pandemic response
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
Reflecting on Mental Health Awareness Month
American leadership on innovation policy is essential to global health progress
Patient safety is at the heart of COVID-19 vaccine R&D
PhRMA member companies share how they are improving clinical trial diversity
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
Diversifying clinical trials and fighting disease requires equity and trust
Building confidence in the COVID-19 vaccine through education
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Fighting variants of COVID-19
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
Top five issues voters want addressed in the administration’s first 100 days
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
Lessons learned from COVID-19: The way we develop new medicines is changing
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Growing trend: Increased vaccine confidence
Election insights: Common ground areas to address Americans’ health care concerns
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
Election insights: Voter priorities in the states
Increasing diversity at investigator sites could increase minority participation in clinical trials
Report highlights biopharmaceutical industry’s commitment to D&I
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Insights from the election: Meeting voters where they are on health care
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
Guest Post: Bringing our best to the fight against COVID-19
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Committing to diversity, equity and inclusion: A call to action for clinical trials
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
Just released: PhRMA members’ new clinical trial diversity principles
Deep dive: The issues that drove the 2020 vote
Understanding the emergency use authorization process for COVID-19 vaccines
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
Voters want to address the real drivers of health care costs for patients and the system
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Sharing rebates can improve access to medicines and increase health equity
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
PhRMA will continue to advocate for equity within our industry
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
Three ways the pharmaceutical industry can positively impact health equity
The 2020 We Work for Health Champion Awards showcase the best of our industry
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
Summer reading in the age of COVID-19
Systemic racism is as real as any disease, and our industry is not immune
The patient perspective navigating COVID-19
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
Executive order threatens R&D when we need it most to fight COVID-19
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
New initiative to bridge the gap on antimicrobial innovation
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
In combating COVID-19, science is how we get back to normal
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Guest post: A post-pandemic crisis: The mental toll on America
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
What scientific experts are saying about vaccine safety
Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
IP Explained: Intellectual property system working to combat COVID-19
Guest Post: What will we learn from COVID-19?
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
Guest Post: Preserving clinical research sites during the coronavirus pandemic
Observing National Minority Health Month in the age of COVID-19
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
Guest post: Securing the health care supply chain during COVID-19
To the millions affected by COVID-19
New infographic: How we are fighting COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
COVID-19 Response: Supporting the frontline
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
America’s biopharmaceutical companies are working around the clock to beat coronavirus
Guest post: Takeda’s efforts to address COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Helping those affected by the coronavirus
"PhRMA awards $100,000 to fund projects that address health inequalities"
Coronavirus
Health Equity
PhRMA awards $100,000 to fund projects that address health inequalities
"PhRMA awards $100,000 to fund projects that address health inequalities"